Kidney failure life expectancy with EGCG
A preliminary study explored the possibility that either EGCG from green tea or resveratrol from red grapes could help protect kidney function from life-threatening failure.
The researchers at Mansoura University in Egypt used the cisplatin laboratory model to create disruption in renal glomerular filtration rate or GFR, a sign of nephrotoxicity that can lead to kidney failure.
Cisplatin is a widely used chemotherapy drug used to treat cancers, including ovarian, testicular, bladder, small cell lung cancer, sarcomas, lymphomas, and germ cell tumors.
Side effects of this chemotherapy drug may include nephrotoxicity and life-threatening damaged kidneys.
The kidney failure life expectancy study looked at biomarkers of oxidative stress and inflammatory cytokines.
1. Animals given a single dose of cisplatin showed
2. Cisplatin plus resveratrol and quercetin at two dosage levels
3. Cisplatin and 50 mg/kg EGCG from green tea (but not 25 mg/kg) showed
The researchers concluded that EGCG showed protection against kidney toxicity caused by the cisplatin drug (El-Mowafy AM et al, Evaluation of renal protective effects of the green-tea (EGCG) and red grape resveratrol: role of oxidative stress and inflammatory cytokines, Nat Prod Res, April 2012).
This animal research is considered preliminary.
More health info with free subscription to the Green Tea Health Newsletter here:
Published and Available on Amazon NOW!
With over 250 pages and 540 referenced scientific studies, this book includes chapters on
Growing lemon balm, Alzheimer's
Anti-bacterial, anti-fungal, anti-microbial, and anti-viral activities
Anti-inflammatory and antioxidant properties, Anxiety
Belly fat, Cancer, Cosmetics, Depression, Diabetes, Heart disease
Herpes and cold sores, Hyperactivity, Indigestion, Insomnia
Irritable bowel syndrome, Memory improvement, Obesity
Premenstrual syndrome, Spinal cord injury, Stress, Thyroid , Ulcers
Order by title from Amazon now, or click the link provided above
This page last updated by Sharon Jones.
Subscribe now and don't miss a single issue.
Find out more!